Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia

Document Details

Document Type
Pub Defense Publication
Publication Date
Oct 01, 2015
Source ID
10.1016/j.bbmt.2015.05.023

Entities

People

  • Alvaro Urbano-ispizua
  • Ami A Shah
  • Amin M. Alousi
  • Ayman Saad
  • Baldeep Wirk
  • Betty K. Hamilton
  • Corey S. Cutler
  • Daniel R. Couriel
  • David I. Marks
  • Gerard Socie
  • Görgün Akpek
  • Joseph H. Antin
  • Martin S. Tallman
  • Mary E.d. Flowers
  • Melhem M. Solh
  • Michael T. Hemmer
  • Mitchell S Cairo
  • Mohamed A Kharfan-Dabaja
  • Mukta Arora
  • Nelson J Chao
  • Olle T.h. Ringdén
  • Paul J. Martin
  • Ran Reshef
  • Robert J. Hayashi
  • Robert Peter Gale
  • Stephen R. Spellman
  • Taiga Nishihori
  • Takanori Teshima
  • Tao Wang
  • Vikas Gupta
  • Yoshihiro Inamoto

Organizations

  • ARIAD Pharmaceuticals
  • Actinium Pharmaceuticals (United States)
  • Amgen
  • Blue Cross Blue Shield Association
  • Celgene
  • Elevance Health, Inc.
  • Fred Hutchinson Cancer Center
  • GSK
  • Health Research
  • HistoGenetics (United States)
  • Incyte
  • Kiadis Pharma (Netherlands)
  • Leukemia & Lymphoma Society
  • Medical College of Wisconsin
  • Merck & Co.
  • Miltenyi Biotec
  • National Cancer Institute
  • National Heart, Lung, and Blood Institute
  • National Institute of Allergy and Infectious Diseases
  • National Marrow Donor Program
  • Office of Naval Research
  • Onyx Pharmaceuticals
  • Osiris Therapeutics
  • Otsuka (United States)
  • Roche (United States)
  • Roswell Park Comprehensive Cancer Center
  • Sanofi-Aventis
  • Seagen
  • Sigma-Tau Pharmaceuticals (United States)
  • St. Baldrick's Foundation
  • StemCyte
  • Swedish Orphan Biovitrum
  • Tarix Orphan (United States)
  • Terumo BCT (United States)
  • University of Minnesota
  • University of Utah

Tags

Technology Areas

  • Biotechnology